Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials

European Archives of Psychiatry and Clinical Neuroscience

Volumn 266, Issue 5, 2016, Pages 439-450

  Oya, Kazuto ^a   Matsuda, Yuki ^a   Matsunaga, Shinji ^a   Kishi, Taro ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Meta analysis; Oxytocin; Schizophrenia; Systematic review

Indexed keywords

NEUROLEPTIC AGENT; OXYTOCIN; PLACEBO; OXYTOCIC AGENT;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; BURNING SENSATION; CONSTIPATION; DATA BASE; DECREASED APPETITE; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEVER; HEADACHE; HEART PALPITATION; HUMAN; INCREASED APPETITE; LETHARGY; MALAISE; META ANALYSIS; MICTURITION DISORDER; NAUSEA; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESTLESSNESS; RISK FACTOR; SALIVATION DISORDER; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SLEEP DISORDER; SORE THROAT; SYSTEMATIC REVIEW; TINNITUS; TREATMENT INDICATION; TREMOR; URTICARIA; VOMITING; XEROSTOMIA; FEMALE; MALE;

FEMALE; HUMANS; MALE; OXYTOCICS; OXYTOCIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84939863948     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-015-0634-9     Document Type: Article

References (34)

1. Andreasen N (1984) Scale for the assessment of negative symptoms (sans). University of Iowa, Iowa City
2. Andreasen N (1984) Scale for the assessment of positive symptoms (saps). Univeristy of Iowa, Iowa City
3. Averbeck BB, Bobin T, Evans S, Shergill SS (2012) Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med 42:259–266
4. Bartz JA, Zaki J, Bolger N, Ochsner KN (2011) Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci 15:301–309
5. Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Scott EM, Naismith SL, Moore L, Alvares GA, Redoblado Hodge MA, Guastella AJ (2015) A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr Bull 41:483–493
6. Chapman CD, Frey WH 2nd, Craft S, Danielyan L, Hallschmid M, Schioth HB, Benedict C (2013) Intranasal treatment of central nervous system dysfunction in humans. Pharm Res 30:2475–2484
7. Davis MC, Green MF, Lee J, Horan WP, Senturk D, Clarke AD, Marder SR (2014) Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 39:2070–2077
8. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A (2010) Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 68:678–680
9. Fischer-Shofty M, Brune M, Ebert A, Shefet D, Levkovitz Y, Shamay-Tsoory SG (2013) Improving social perception in schizophrenia: the role of oxytocin. Schizophr Res 146:357–362
10. Fischer-Shofty M, Shamay-Tsoory SG, Levkovitz Y (2013) Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls. Front Neurosci 7:127
11. Forbes C, Blanchard JJ, Bennett M, Horan WP, Kring A, Gur R (2010) Initial development and preliminary validation of a new negative symptom measure: the clinical assessment interview for negative symptoms (cains). Schizophr Res 124:36–42
12. Gibson CM, Penn DL, Smedley KL, Leserman J, Elliott T, Pedersen CA (2014) A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr Res 156:261–265
13. Goldman MB, Gomes AM, Carter CS, Lee R (2011) Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology 216:101–110
14. Green S (2005) Systematic reviews and meta-analysis. Singap Med J 46:270–273 quiz 274
15. Gumley A, Braehler C, Macbeth A (2014) A meta-analysis and theoretical critique of oxytocin and psychosis: prospects for attachment and compassion in promoting recovery. Br J Clin Psychol 53:42–61
16. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Statistical Methods G, Cochrane Statistical Methods G (2011) The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
17. Holka-Pokorska J, Jarema M (2014) oxytocin model of formation of psychotic symptoms and its implications for research on oxytocinergic pathway in schizophrenia. Psychiatry Pol 48:19–33
18. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (panss) for schizophrenia. Schizophr Bull 13:261–276
19. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005) Oxytocin increases trust in humans. Nature 435:673–676
20. Lee MR, Wehring HJ, McMahon RP, Linthicum J, Cascella N, Liu F, Bellack A, Buchanan RW, Strauss GP, Contoreggi C, Kelly DL (2013) Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res 145:110–115
21. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41
22. MacDonald AW, Schulz SC (2009) What we know: findings that every theory of schizophrenia should explain. Schizophr Bull 35:493–508
23. McGregor IS, Callaghan PD, Hunt GE (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use? Br J Pharmacol 154:358–368
24. Meltzer HY (2004) Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr 9:15–24
25. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12:524–538
26. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:1206–1227
27. Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S (2013) Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 27:57–65
28. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. BMJ 339:b2535
29. Neumann ID, Landgraf R (2012) Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 35:649–659
30. Overall J, Gorham D (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812
31. Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, Leserman J, Jarskog LF, Penn DL (2011) Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr Res 132:50–53
32. Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, Losardo D, Lieberman JA (2009) The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the catie trial. Schizophr Res 115:17–23
33. Theodoridou A, Rowe AC, Penton-Voak IS, Rogers PJ (2009) Oxytocin and social perception: oxytocin increases perceived facial trustworthiness and attractiveness. Horm Behav 56:128–132
34. Walters Y, Agius M (2014) Do atypical antipsychotics improve cognition? Psychiatr Danub 26(Suppl 1):285–288